B7-1 Engagement of Cytotoxic T Lymphocyte Antigen 4 Inhibits T Cell Activation in the Absence of CD28
Open Access
- 1 July 1998
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 188 (1) , 205-210
- https://doi.org/10.1084/jem.188.1.205
Abstract
Ligation of cytotoxic T lymphocyte antigen 4 (CTLA4) appears to inhibit T cell responses. Four mechanisms have been proposed to explain the inhibitory activity of CTLA4: competition for B7-1 and B7-2 binding by CD28; sequestration of signaling molecules away from CD28 via endocytosis; delivery of a signal that antagonizes a CD28 signal; and delivery of a signal that antagonizes a T cell receptor (TCR) signal. As three of these potential mechanisms involve functional antagonism of CD28, an experimental model was designed to determine whether CTLA4 could inhibit T cell function in the absence of CD28. TCR transgenic/recombinase activating gene 2–deficient/CD28–wild-type or CD28-deficient mice were generated and immunized with an antigen-expressing tumor. Primed T cells from both types of mice produced cytokines and proliferated in response to stimulator cells lacking B7 expression. However, whereas the response of CD28+/+ T cells was augmented by costimulation with B7-1, the response of the CD28−/− T cells was strongly inhibited. This inhibition was reversed by monoclonal antibody against B7-1 or CTLA4. Thus, CTLA4 can potently inhibit T cell activation in the absence of CD28, indicating that antagonism of a TCR-mediated signal is sufficient to explain the inhibitory effect of CTLA4.Keywords
This publication has 33 references indexed in Scilit:
- The Emerging Role of CTLA-4 as an Immune AttenuatorImmunity, 1997
- CD28/B7 SYSTEM OF T CELL COSTIMULATIONAnnual Review of Immunology, 1996
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996
- SKIN ALLOGRAFT REJECTION IN CD28-DEFICIENT MICE1Transplantation, 1996
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4Science, 1995
- Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4Immunity, 1995
- Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptorsImmunity, 1994
- CTLA-4 can function as a negative regulator of T cell activationImmunity, 1994
- Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1.The Journal of Experimental Medicine, 1993
- CTLA-4 is a second receptor for the B cell activation antigen B7.The Journal of Experimental Medicine, 1991